Brief: Sensorion Partners With Institut Pasteur On Gene Therapy Programs

Sensorion SA

05/01/2024 06:33

Jan 5 (Reuters) - Sensorion SA  ALSEN.PA :
    * ANNOUNCES PARTNERSHIP WITH THE INSTITUT PASTEUR TO
ACCELERATE
GENE THERAPY PROGRAMS TARGETING HEARING DISORDERS HAS BEEN
EXTENDED FOR FIVE YEARS
    * SENS-501, MOST ADVANCED PROGRAM WITHIN PARTNERSHIP THAT
TARGETS
DEAFNESS CAUSED BY MUTATIONS IN GENE CODING FOR OTOFERLIN,
DEFINED AS A PRIORITY IN 2019, HAS MET ITS OBJECTIVES
    * SUCCESSFUL COMPLETION OF EFFICACY PRECLINICAL PACKAGE IN
FRAME
OF COLLABORATION BETWEEN SENSORION AND INSTITUT PASTEUR ADVANCED
PROGRAM WITH DEVELOPMENT OF OTOF-GT PRODUCT (SENS-501) TOWARDS
CLINICAL STAGE

Source text for Eikon:  ID:nBw1yXXDSa 
Further company coverage:  ALSEN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))